Pfizer is “excited” about breaking into oncology biosimilars in the US, given the oncology market’s “different dynamics” that typically result in higher and faster biosimilar uptake, especially in light of the US-based player’s struggles to gain a meaningful US market share for its Inflectra (infliximab-dyyb) autoimmune diseases biosimilar.
Pfizer is “excited” about breaking into oncology biosimilars in the US, given the oncology market’s “different dynamics” that typically result in higher and faster biosimilar uptake, especially in light of the US-based player’s struggles to gain a meaningful US market share for its Inflectra (infliximab-dyyb) autoimmune diseases biosimilar.
“We see different dynamics in that the duration of treatment [for oncology] is shorter, therefore you’re going to get new...
Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
